UK – NICE recommends Roche’s Tecentriq for metastatic NSCLC

NICE has published final draft guidance recommending Roche’s Tecentriq in combination with other therapies for metastatic non-squamous, non-small-cell lung cancer, after a new deal for the drug combination now means it is cost effective.

The recommendation is for use of the drug in combination with Avastin (bevacizumab), carboplatin and paclitaxel for patients who have not had treatment for their metastatic NSCLC before, and whose PD-L1 tumour proportion score is between 0% and 49%. Also when targeted therapy for epidermal growth factor receptor (EGFR)- positive or anaplastic lymphoma kinase (ALK)-positive NSCLC has failed.

The new deal was made on the basis that treatment with Tecentriq and Avastin is stopped at two years to reflect the fact that the cost-effectiveness evidence was limited to two years of treatment and the best length of treatment is unknown.

In trials, those who received carboplatin and paclitaxel live longer than those having the current treatment of pemetrexed plus carboplatin or cisplatin, with or without pemetrexed maintenance, as well as living for longer before their condition worsens…